Using cognitive bias modification to improve treatment for OCD
Interpretation Bias as a Mechanism of Treatment Response in OCD
NA · Mclean Hospital · NCT05224414
This study is testing if a new digital program that helps change how people think can improve treatment for adults with obsessive-compulsive disorder (OCD).
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 106 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mclean Hospital (other) |
| Locations | 1 site (Belmont, Massachusetts) |
| Trial ID | NCT05224414 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Cognitive Bias Modification for Interpretation (CBM-I) as an additional treatment for adults with obsessive-compulsive disorder (OCD). Participants will be randomly assigned to receive either CBM-I, which involves a digital intervention aimed at altering interpretation biases, or psychoeducation as a control. The study will assess the feasibility, acceptability, and clinical outcomes of the intervention over a series of sessions. The goal is to determine if this approach can enhance treatment outcomes for individuals with OCD.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a primary diagnosis of OCD who are currently receiving treatment.
Not a fit: Patients experiencing acute symptoms of psychosis or with a psychotic disorder diagnosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could lead to improved treatment outcomes for patients with OCD by addressing cognitive biases.
How similar studies have performed: While the specific approach of CBM-I may be novel, similar cognitive interventions have shown promise in improving treatment outcomes in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\) OCD Institute patients * 2\) adults (\> 18 years old) * 3\) able to complete a computer task for 20 minutes * 4\) consent to main OCD Institute study protocol * 5\) primary diagnosis of OCD (as measured by a score of \>16 on the Y-BOCS and a clinical diagnosis of OCD by their treatment team * 6\) score of \>131 on the Obsessive Beliefs Questionnaire-44 at admission \[which is 1 SD above the mean score of the non-clinical sample reported in the original validation paper by the Obsessive Compulsive Cognitions Working Group (2005)\] Exclusion Criteria: * 1\) Currently experiencing acute symptoms of psychosis * 2\) Psychotic disorder diagnosis
Where this trial is running
Belmont, Massachusetts
- McLean Hospital — Belmont, Massachusetts, United States (RECRUITING)
Study contacts
- Study coordinator: Martha Falkenstein, PhD
- Email: mfalkenstein@mclean.harvard.edu
- Phone: 617-855-4424
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Obsessive-Compulsive Disorder